Skip to main content
Top
Published in: Clinical Rheumatology 4/2007

01-04-2007 | Original Article

Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis

Identification of a relatively benign subgroup

Authors: E. J. ter Borg, H. C. M. Haanen, C. A. Seldenrijk

Published in: Clinical Rheumatology | Issue 4/2007

Login to get access

Abstract

Temporal arteritis (TA) may offer major complications, whilst high dosage of prednisone may result in serious side effects. We tried to identify a subgroup of TA, which can be treated with a lower dosage of prednisone. Retrospectively, clinical and laboratory data were studied at presentation, as well as the outcome in 44 consecutive patients with biopsy-proven temporal arteritis. These data were related to three particular histological subgroups, (a) classical giant cell arteritis, (b) atypical arteritis, and (c) ‘healed arteritis’, defined according to Allsop and Gallagher (The American Journal of Surgical Pathology 5:317–332, 1981). At presentation in subgroup c, erythrocyte sedimentation rate was lower and the level of haemoglobin was higher than in the other two subgroups. During follow-up in the healed arteritis group, reactivation, recurrence, or early death were not observed, whilst prednisone dosage after 2 and 3 years was lower compared to subgroup b. Major complications (permanent blindness and cerebrovascular accident) were only observed in subgroups a and b. We believe that the healed arteritis subgroup represents a relatively benign subgroup with a mild clinical presentation and a good prognosis. Therefore, a much lower initial prednisone dosage (15 mg/day) is suggested for patients in subgroup c than in the other two subgroups (40–60 mg/day).
Literature
1.
go back to reference Allsop CJ, Gallagher PJ (1981) Temporal artery biopsy in giant-cell arteritis. Am J Surg Pathol 5:317–332PubMedCrossRef Allsop CJ, Gallagher PJ (1981) Temporal artery biopsy in giant-cell arteritis. Am J Surg Pathol 5:317–332PubMedCrossRef
2.
go back to reference Evans JM, Hunder GG (2000) Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 26(3):493–515PubMedCrossRef Evans JM, Hunder GG (2000) Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 26(3):493–515PubMedCrossRef
3.
go back to reference Hunder CG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128PubMedCrossRef Hunder CG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128PubMedCrossRef
4.
go back to reference Healy LA, Parker F, Wilske KR (1971) Polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 14:138–141CrossRef Healy LA, Parker F, Wilske KR (1971) Polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 14:138–141CrossRef
5.
go back to reference Chmelewski WL, McKnight KM, Agudelo CA, Wise CM (1992) Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med 152:1690–1995PubMedCrossRef Chmelewski WL, McKnight KM, Agudelo CA, Wise CM (1992) Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med 152:1690–1995PubMedCrossRef
Metadata
Title
Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis
Identification of a relatively benign subgroup
Authors
E. J. ter Borg
H. C. M. Haanen
C. A. Seldenrijk
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0332-0

Other articles of this Issue 4/2007

Clinical Rheumatology 4/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.